4 Result: Sanofi
FDA Approves New Indication for Tzield (teplizumab) for Certain Pediatric Patients with Recently Diagnosed Stage 3 Type 1 Diabetes
June 15th, 2026
First disease modifying therapy approval for new onset stage 3 diabetes represents a significant milestone for the pediatric type 1 diabetes community Silver Spring, MD / CRWE PRESS RELEASE / June 15, 2026 - On June 12, 2026, the U.S. F. Read more
Acuity Brands Posts Mixed Results; Sanofi, Teva Ink Anti-TL1A Therapy Deal
October 04th, 2023
Acuity Brands, Inc. (NYSE: AYI) posted fourth-quarter fiscal 2023 earnings of $3.97 per share, surpassing the consensus EPS estimate of $3.72. Quarterly sales for the company totaled $1.01 billion, slightly below analysts' revenue projections of $1.0. Read more
Breaking: Sanofi's Legal Win, Innovative Eyewear's License Deal
June 20th, 2023
Shares of Sanofi (Nasdaq: SNY) surged in pre-market trading following the announcement of a favorable outcome in an International Chamber of Commerce dispute. The tribunal ruled in favor of Sanofi, dismissing Boehringer Ingelheim's. Read more
Innate Pharma, Sanofi: FDA Grants FTD to SAR'579/IPH6101; Hyzon Motors Posts Q1 Loss - IPHA, HYZN News
June 08th, 2023
Innate Pharma (Nasdaq: IPHA) shared important news from Sanofi (Nasdaq: SNY) regarding the U.S. Food and Drug Administration (FDA) granting Fast Track Designation for SAR'579 / IPH6101 to treat hematological malignancies. The FDA's Fast Trac. Read more
Want To Find Some News?
News By Industries
Recent Post
-
FAA and EASA Pledge Cooperation for the New Era of Aviation
June 18th, 2026June 17th, 2026June 15th, 2026
Member Login